The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.
The National Clinical Research Center for Mental Disorders, China &Center of Depression, Beijing Institute for Brain Disorders & Mood Disorders Center, Beijing Anding Hospital, Capital Medical University, Beijing, China.
J Psychiatr Res. 2018 Aug;103:38-45. doi: 10.1016/j.jpsychires.2018.05.001. Epub 2018 May 5.
Findings of neurocognitive dysfunction in subjects at Clinical High Risk for Psychosis (CHR-P) have been controversial. This meta-analysis systematically examined studies of neurocognitive functions using the MATRICS Consensus Cognitive Battery (MCCB) in CHR-P. An independent literature search of both English and Chinese databases was conducted by two reviewers. Standardized mean difference (SMD) was calculated using a random effects model to evaluate the effect size of the meta-analytic results. Six case-control studies (n = 396) comparing neurocognitive functions between CHR-P subjects (n = 197) and healthy controls (n = 199) using the MCCB were identified; 4 (66.7%) studies were rated as "high quality". Compared to healthy controls, CHR-P subjects showed impairment with large effect size in overall cognition (n = 128, SMD = -1.00, 95%CI: -1.38, -0.63, P < 0.00001; I = 2%), processing speed (SMD = -1.21) and attention/vigilance (SMD = -0.83), and with medium effect size in working memory (SMD = -0.76), reasoning and problem solving (SMD = -0.71), visual (SMD = -0.68) and verbal learning (SMD = -0.67). No significant difference between CHR-P subjects and controls was found regarding social cognition (SMD = -0.33, 95%CI: -0.76, 0.10, P = 0.14; I = 70%) with small effect size. Apart from social cognition, CHR-P subjects performed worse than healthy control in all MCCB cognitive domains, particularly in processing speed, attention/vigilance and working memory.
临床精神病高危人群(CHR-P)的神经认知功能障碍的研究结果一直存在争议。本荟萃分析系统地研究了使用 MATRICS 共识认知电池(MCCB)的 CHR-P 中的神经认知功能。两位评审员独立地对中英文数据库进行了文献检索。使用随机效应模型计算标准化均数差(SMD),以评估荟萃分析结果的效应大小。共确定了 6 项病例对照研究(n=396),比较了使用 MCCB 的 CHR-P 受试者(n=197)和健康对照组(n=199)之间的神经认知功能;其中 4 项(66.7%)研究被评为“高质量”。与健康对照组相比,CHR-P 受试者在整体认知(n=128,SMD=-1.00,95%CI:-1.38,-0.63,P<0.00001;I²=2%)、加工速度(SMD=-1.21)和注意力/警觉性(SMD=-0.83)方面表现出明显的损害,并且在工作记忆(SMD=-0.76)、推理和解决问题(SMD=-0.71)、视空间(SMD=-0.68)和言语学习(SMD=-0.67)方面也表现出中等程度的损害。在社会认知(SMD=-0.33,95%CI:-0.76,0.10,P=0.14;I²=70%)方面,CHR-P 受试者与对照组之间无显著差异,效应大小较小。除了社会认知,CHR-P 受试者在所有 MCCB 认知领域的表现均差于健康对照组,特别是在加工速度、注意力/警觉性和工作记忆方面。
J Psychiatr Res. 2018-5-5
J Psychiatr Res. 2017-10-19
Eur Arch Psychiatry Clin Neurosci. 2016-2
Schizophrenia (Heidelb). 2025-7-1
Biomark Neuropsychiatry. 2024-12
Eur Arch Psychiatry Clin Neurosci. 2024-9
Front Psychiatry. 2023-9-8